CD38 and Miyoshi myopathy: One such monoclonal antibody is daratumumab (Darzalex®), which is a first-in-class anti-CD38 monoclonal antibody for MM treatment approved by the Food and Drug Administration (FDA) as a monotherapy for relapsed and refractory MM in 2015 and in combination with either bortezomib and dexamethasone or lenalidomide and dexamethasone in 2016 [2,5].